| __timestamp | Protagonist Therapeutics, Inc. | Ultragenyx Pharmaceutical Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 1860000 | 10811000 |
| Thursday, January 1, 2015 | 2963000 | 33001000 |
| Friday, January 1, 2016 | 6961000 | 64936000 |
| Sunday, January 1, 2017 | 11779000 | 99909000 |
| Monday, January 1, 2018 | 13697000 | 127724000 |
| Tuesday, January 1, 2019 | 15749000 | 161524000 |
| Wednesday, January 1, 2020 | 18638000 | 182933000 |
| Friday, January 1, 2021 | 27196000 | 219982000 |
| Saturday, January 1, 2022 | 31739000 | 278139000 |
| Sunday, January 1, 2023 | 33491000 | 309799000 |
Data in motion
In the competitive landscape of biotechnology, understanding financial trends is crucial. Over the past decade, Ultragenyx Pharmaceutical Inc. and Protagonist Therapeutics, Inc. have shown distinct trajectories in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Ultragenyx's SG&A expenses surged by nearly 2,800%, reflecting its aggressive growth strategy. In contrast, Protagonist's expenses increased by approximately 1,700%, indicating a more measured expansion.
These trends highlight Ultragenyx's robust investment in operational capabilities, while Protagonist's steady rise suggests strategic scaling. Investors and stakeholders should consider these financial patterns when evaluating future prospects.
Cost Management Insights: SG&A Expenses for Vertex Pharmaceuticals Incorporated and Ultragenyx Pharmaceutical Inc.
Who Optimizes SG&A Costs Better? Regeneron Pharmaceuticals, Inc. or Ultragenyx Pharmaceutical Inc.
Selling, General, and Administrative Costs: Takeda Pharmaceutical Company Limited vs Protagonist Therapeutics, Inc.
SG&A Efficiency Analysis: Comparing Alnylam Pharmaceuticals, Inc. and Ultragenyx Pharmaceutical Inc.
Comparing SG&A Expenses: Teva Pharmaceutical Industries Limited vs Ultragenyx Pharmaceutical Inc. Trends and Insights
Cost Management Insights: SG&A Expenses for Neurocrine Biosciences, Inc. and Ultragenyx Pharmaceutical Inc.
Alkermes plc or Ultragenyx Pharmaceutical Inc.: Who Manages SG&A Costs Better?
Ultragenyx Pharmaceutical Inc. vs Apellis Pharmaceuticals, Inc.: SG&A Expense Trends
Comparing SG&A Expenses: Ultragenyx Pharmaceutical Inc. vs Perrigo Company plc Trends and Insights
Selling, General, and Administrative Costs: Ultragenyx Pharmaceutical Inc. vs Taro Pharmaceutical Industries Ltd.
Cost Management Insights: SG&A Expenses for Ultragenyx Pharmaceutical Inc. and BioCryst Pharmaceuticals, Inc.
Viking Therapeutics, Inc. or Protagonist Therapeutics, Inc.: Who Manages SG&A Costs Better?